| 2015 |
Surv.m-CRA-1 preclinical research selected as a research project under the “Practical Research for Innovative Cancer Control” grant program of the Japan Agency for Medical Research and Development (AMED) |
| 2016 |
Commenced investigator-initiated P1 first-in-human clinical study on Surv.m-CRA-1 |
| 2019 |
Surv.m-CRA-1 clinical research selected under AMED’s “Strategic Promotion Program for Translational Research” grant program (Category “Seed C” for clinical POC) |
| 2021 |
Surv.m-CRA-1 clinical research selected as a research project under AMED’s “Practical Research for Innovative Cancer Control” grant program |
| 2022 Aug |
Surv BioPharma Inc. established in Kagoshima City as a drug discovery venture company originating from Kagoshima University |
| 2022 Dec |
Opened Tokyo Office in the Nihonbashi Life Science Building in Tokyo |
| 2022 Dec |
Signed funding agreement with DCI Partners Co., Ltd. and Kagoshima Bank offshoot Kagoshima Development Co., Ltd. (total funding: JPY 1 billion) |
| 2023 Apr |
Relocated Head Office to Kagoshima University’s Sakuragaoka Campus |
| 2023 Nov |
Signed joint research agreement with Kagoshima University |
| 2023 Nov |
Signed patent licensing agreement with Kagoshima University |
| 2024 |
Surv.m-CRA-1 clinical research selected under AMED’s “Strategic Promotion Program for Translational Research” grant program (Category “Seed F” for clinical POC based on academia-industry collaboration) |
